<DOC>
	<DOCNO>NCT00636259</DOCNO>
	<brief_summary>This study provide compassionate use bicalutamide ( Casodex ) 150-mg dose subject prostate cancer prior become commercially available . The patient receive bicalutamide 150-mg long physician feel subject benefit therapy safety information provide regularly AstraZeneca . Treatment discontinue bicalutamide 150-mg becomes commercially available .</brief_summary>
	<brief_title>Casodex 150-mg Compassionate Use Trial Subjects With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Patients adenocarcinoma prostate Subjects locally advance , and/or metastatic prostate cancer surgical castration medical intervention consider appropriate acceptable Any known history abnormal liver function test Any severe concomitant condition would make undesirable , clinician 's opinion , subject participate trial . Known hypersensitivity bicalutamide component find bicalutamide</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Casodex</keyword>
</DOC>